Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment.

Oliver Sartor, MD highlighted SBRT, hormonal therapy, and the PSMA-DC regimen for patients with biochemical recurrence and PSMA-PET–positive disease.

Sagar Lonial, MD, discusses the expanding potential uses of cereblon E3 ligase modulators (CELMoDs) in combination with T-cell redirection therapies in multiple myeloma.

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance.

Rami Komrokji, MD, discusses strategies and barriers for utilizing current risk-stratification tools in myelodysplastic syndromes.

Shubham Pant, MD, MBBS, discusses data from the phase 3 BREAKWATER trial supporting upfront targeted therapy in BRAF V600E–mutant mCRC.

Report finds hospitals price the same cancer drugs up to 2000x apart, worsening financial toxicity and intensifying demands for real transparency.

Yan Leyfman, MD, discussed the factors that may ultimately define the next era of transplant medicine across hematologic malignancies.

PMD-026 inhibits RSK to block tumor growth signals and ER activity, a potential strategy to overcome CDK4/6 inhibitor resistance in breast cancer.

Toni K. Choueiri, MD, discusses safety data from the phase 3 LITESPARK-022 study in ccRCC.

Drs Tiesi, Scholer, and Pletcher discuss the growing role for TAMP as a regional therapy strategy for patients with locally advanced PDAC.

Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates.

Denileukin diftitox brings a new systemic option for relapsed CTCL, killing tumor cells and Tregs to boost immunity and expand EU access.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Among patients who discontinued enfortumab vedotin due to an ongoing response or toxicity, 57% were treatment-free and alive 1 year later.

Key experts across oncology specialties share how they prioritize patient safety in their practices related to AE awareness and mitigation strategies.

Although the 5-year survival rate has improved to about 13 percent, pancreatic cancer remains one of the deadliest cancers, often diagnosed at advanced stages with limited treatment options.

Althopugh current prostate cancer biomarkers have improved the detection of clinically significant disease (Gleason Grade Group 2+), they fail to distinguish between high-grade cancer and genuinely lethal cancer, potentially leading to overtreatment and underscoring the need for next-generation tools that identify patients at true mortality risk.

The phase 3 TACTI-004 trial has been discontinued in patients with NSCLC in accordance with an independent data monitoring committee recommendation.

Integrating a medically supervised ketogenic diet with gemcitabine, nab-paclitaxel, and cisplatin significantly extends OS in those with metastatic PDAC.

In an interview, Vincent Ma, MD, explores the clinical utility of circulating tumor DNA dynamics to assess early outcomes in patients with melanoma.

Laura J. Esserman, MD, MBA, discusses the potential utility of risk-based screening for breast cancer.

Javid Moslehi, MD, discusses the role of the cardiologist in the setting of breast cancer management to facilitate optimal cancer management.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss ongoing research shaping EGFR-mutated NSCLC care.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss clinical experience with antibody-drug conjugates in EGFR-mutated NSCLC.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss remaining evidence gaps in EGFR-mutated NSCLC care.

Natalie Vokes, MD, and Sid Devarakonda, MBBS, MD, discuss resistance mechanisms in EGFR-mutated NSCLC.

This segment explores how long-term survival data and real-world experience inform decisions about maintenance immunotherapy in advanced urothelial (bladder) cancer.

Panelists review a patient with DLBCL relapsing 8 months after frontline Pola-R-CHP following an initial complete response. With low symptom burden and favorable performance status, the debate centers on optimal second-line strategy, outpatient CAR T feasibility, caregiver limitations, and balancing treatment intensity with quality-of-life and employment considerations in an urban setting.

In this segment, Dr. Devarakonda asks Dr. Rotow to outline the advantages and limitations of combination regimens compared with single agent EGFR tyrosine kinase inhibitors in the first line treatment of EGFR mutated metastatic non-small cell lung cancer.